Leukemia Research Reports最新文献

筛选
英文 中文
Is Bartonella sp. infection relevant in hematological malignancies in HIV-negative patients? A literature review 巴顿氏菌感染与 HIV 阴性患者的血液恶性肿瘤有关吗?文献综述
Leukemia Research Reports Pub Date : 2023-12-13 DOI: 10.1016/j.lrr.2023.100402
Elisa Nunes Secamilli , Marina Rovani Drummond , Juliana Yumi Massuda Serrano , Rafael Fantelli Stelini , Maria Leticia Cintra , Paulo Eduardo Neves Ferreira Velho
{"title":"Is Bartonella sp. infection relevant in hematological malignancies in HIV-negative patients? A literature review","authors":"Elisa Nunes Secamilli ,&nbsp;Marina Rovani Drummond ,&nbsp;Juliana Yumi Massuda Serrano ,&nbsp;Rafael Fantelli Stelini ,&nbsp;Maria Leticia Cintra ,&nbsp;Paulo Eduardo Neves Ferreira Velho","doi":"10.1016/j.lrr.2023.100402","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100402","url":null,"abstract":"<div><p>Bartonelloses are diseases caused by Bartonella sp., transmitted to humans by blood sucking arthropod vectors. Clinical presentations include bacillary angiomatosis, cat scratch disease and atypical forms. We performed a review of cases of bartonelloses and hematological malignancies published in HIV-negative patients. Terms used were Bartonella or Bacillary Angiomatosis and Leukemia, Lymphoma, Multiple Myeloma, or Cancer. Fifteen cases met our criteria. Clinical presentations included bacillary angiomatosis, chronic fever, chronic lymphadenopathy, osteomyelitis, neuroretinitis, chronic anemia and hepatosplenic peliosis. Fourteen patients were asymptomatic after antibiotic therapy, and one died before antibiotic treatment. Clinicians should be suspicious of Bartonella sp. infections in immunocompromised patients.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100402"},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000420/pdfft?md5=1a9b43ce6cf272c312719dbe2980b7ad&pid=1-s2.0-S2213048923000420-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138738946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological and clinical characteristics of adult acute lymphoblastic leukemia patients in Chile: A single-center analysis 智利成人急性淋巴细胞白血病患者的流行病学和临床特征:单中心分析
Leukemia Research Reports Pub Date : 2023-12-12 DOI: 10.1016/j.lrr.2023.100405
Joaquín Jerez , Valentina Goldschmidt , María Carolina Guerra , José Luis Briones , Carlos Torres , Sebastián Hidalgo , Raimundo Gazitúa
{"title":"Epidemiological and clinical characteristics of adult acute lymphoblastic leukemia patients in Chile: A single-center analysis","authors":"Joaquín Jerez ,&nbsp;Valentina Goldschmidt ,&nbsp;María Carolina Guerra ,&nbsp;José Luis Briones ,&nbsp;Carlos Torres ,&nbsp;Sebastián Hidalgo ,&nbsp;Raimundo Gazitúa","doi":"10.1016/j.lrr.2023.100405","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100405","url":null,"abstract":"<div><h3>Background</h3><p>Acute lymphoblastic leukemia represents 20% of acute leukemias in adults. Currently, there is limited data in Chile regarding the clinical, cytogenetic, and prognostic characteristics of this condition.</p></div><div><h3>Methods</h3><p>This is a retrospective, observational, and descriptive study of 67 patients treated for acute lymphoblastic leukemia at the Arturo Lopez Perez Foundation between 2018 and 2021. The main objective is to evaluate epidemiological and clinical characteristics, as well as identifying factors associated with improved overall survival and/or progression-free survival.</p></div><div><h3>Results</h3><p>88% of the cases were B-lineage, mainly the common B phenotype. Cytogenetic analysis was performed in less than 50% of the patients, with lower yield than expected according to the literature. Molecular testing was performed in 86.5% of the patients, with the most frequent alteration being BCR-ABL. No study was performed to search for Ph-like abnormalities. The rate of complete response after induction was 83.3%, the majority of patients having negative minimal residual disease. Only 12% of the patients received consolidation with allogenic bone marrow transplant. At 2 years, the overall survival was 69% and the progression-free survival was 59%.</p></div><div><h3>Conclusion</h3><p>The results in terms of overall survival and progression-free survival are similar to those reported in the literature. Important diagnostic gaps prevent adequate prognostic characterization. Allogeneic consolidation transplantation was performed in a lower percentage than expected, highlighting the national deficit in access to this treatment.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100405"},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000456/pdfft?md5=0ad92285cf180884a604004f85fa3f0a&pid=1-s2.0-S2213048923000456-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138657109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare association of a high grade glioblastoma, cerebral abscess and acute lymphoblastic leukemia in a child with Noonan syndrome 一名患有努南综合征的儿童罕见地同时患有高级别胶质母细胞瘤、脑脓肿和急性淋巴细胞白血病
Leukemia Research Reports Pub Date : 2023-12-01 DOI: 10.1016/j.lrr.2023.100404
Wiem Boufrikha , Rim Rakez , Inaam Bizid , M.Maher Hadhri , Manel Njima , Sarra Boukhris , M.Adnene Laatiri
{"title":"A rare association of a high grade glioblastoma, cerebral abscess and acute lymphoblastic leukemia in a child with Noonan syndrome","authors":"Wiem Boufrikha ,&nbsp;Rim Rakez ,&nbsp;Inaam Bizid ,&nbsp;M.Maher Hadhri ,&nbsp;Manel Njima ,&nbsp;Sarra Boukhris ,&nbsp;M.Adnene Laatiri","doi":"10.1016/j.lrr.2023.100404","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100404","url":null,"abstract":"<div><p>Noonan syndrome is a genetic disorder frequently caused by PTPN11 mutations. Patients with Noonan syndrome are characterized by facial dysmorphism, short stature and congenital heart defects and they have a reported predisposition to malignancies such as leukemia, and solid and central nervous system tumors. Here, we report a case of a 14-year-old boy with Noonan syndrome treated for T-cell acute lymphoblastic leukemia who presented with 2 concomitant abnormalities: cerebral abscess and high grade glioblastoma. This exceptional association exhibits to a poorer prognosis and may sometimes delay the diagnosis and therefore the therapeutic intervention.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100404"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000444/pdfft?md5=485634e1df05d16d4b5e9d39874e4c59&pid=1-s2.0-S2213048923000444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138558773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight CAR - t细胞治疗复发/难治性多发性骨髓瘤后严重的SARS-CoV-2和随后的真菌感染:一场具有挑战性和圆满结局的战斗
Leukemia Research Reports Pub Date : 2023-11-27 DOI: 10.1016/j.lrr.2023.100399
Claudia Ielo , Francesca Fazio , Serena Rocchi , Ilaria Rizzello , Katia Mancuso , Elena Zamagni , Michele Cavo , Maria Teresa Petrucci
{"title":"Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight","authors":"Claudia Ielo ,&nbsp;Francesca Fazio ,&nbsp;Serena Rocchi ,&nbsp;Ilaria Rizzello ,&nbsp;Katia Mancuso ,&nbsp;Elena Zamagni ,&nbsp;Michele Cavo ,&nbsp;Maria Teresa Petrucci","doi":"10.1016/j.lrr.2023.100399","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100399","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines. Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100399"},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000390/pdfft?md5=4e2ddeb4f3340dbb5caa3b39552a8b51&pid=1-s2.0-S2213048923000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138467500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular large B-cell lymphoma masquerading as stroke successfully treated with R-Hyper-CVAD 用R-Hyper-CVAD成功治疗伪装成中风的血管内大b细胞淋巴瘤
Leukemia Research Reports Pub Date : 2023-11-27 DOI: 10.1016/j.lrr.2023.100401
Christopher Popiolek , Kanchan Gupta , Mallorie L. Huff , Ranju Gupta
{"title":"Intravascular large B-cell lymphoma masquerading as stroke successfully treated with R-Hyper-CVAD","authors":"Christopher Popiolek ,&nbsp;Kanchan Gupta ,&nbsp;Mallorie L. Huff ,&nbsp;Ranju Gupta","doi":"10.1016/j.lrr.2023.100401","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100401","url":null,"abstract":"<div><p>Intravascular large B cell lymphoma (IVLBCL) is exceedingly rare and difficult to diagnose. We describe a case of IVLBCL in a 56-year-old male which was identified after recurrent strokes. Right partial nephrectomy was then performed which demonstrated renal oncocytoma and IVLBCL. Chemotherapy was initiated with standard R-Hyper-CVAD which included intrathecal methotrexate and cytarabine. R-CHOP is largely considered the treatment of choice in IVLBCL, however low doses of chemotherapy in this regimen do not cross the blood brain barrier like in R-Hyper-CVAD. The patient achieved complete remission after completion of treatment and has remained in remission for 5 years after diagnosis.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100401"},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000419/pdfft?md5=08cf857daa5bc968c89b065b100a4623&pid=1-s2.0-S2213048923000419-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia cutis with KMT2A::MLLT3 fusion presenting with leonine facies KMT2A::MLLT3融合的急性髓性白血病切面表现为腱鞘面容
Leukemia Research Reports Pub Date : 2023-11-24 DOI: 10.1016/j.lrr.2023.100400
Bret Wankel , Muhammad Afzal , Eric Y. Loo , Robert E. LeBlanc , Joi B. Carter , Erick Lansigan , Swaroopa Yerrabothala
{"title":"Acute myeloid leukemia cutis with KMT2A::MLLT3 fusion presenting with leonine facies","authors":"Bret Wankel ,&nbsp;Muhammad Afzal ,&nbsp;Eric Y. Loo ,&nbsp;Robert E. LeBlanc ,&nbsp;Joi B. Carter ,&nbsp;Erick Lansigan ,&nbsp;Swaroopa Yerrabothala","doi":"10.1016/j.lrr.2023.100400","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100400","url":null,"abstract":"<div><p>A 63-year-old woman presented with plaques covering 60 % body-surface-area and leonine facies. Blood work showed no diagnostic aberrancies. Skin biopsy contained a malignant CD4+/CD56+ mononuclear cell population concerning for blastic plasmacytoid dendritic cell neoplasm. A later bone marrow biopsy confirmed AML with <em>KMT2A::MLLT10</em> fusion detected by next-generation sequencing (NGS). This patient's LC preceded blood and marrow based symptoms of AML. NGS of the initial skin biopsy should be considered as part of diagnostic guidelines in cases with LC in the differential as this may have led to earlier diagnosis in this case and future cases.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100400"},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000407/pdfft?md5=0b19d4c2e00f403b405770ee31b33ff3&pid=1-s2.0-S2213048923000407-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas 结合了 LAT1 底物和细胞毒性分子的两种新型双功能化疗化合物在侵袭性 T 细胞淋巴瘤中成功发挥了抗肿瘤作用
Leukemia Research Reports Pub Date : 2023-11-22 DOI: 10.1016/j.lrr.2023.100398
Carlos Murga-Zamalloa , Shaun Webb , John Reneau , Alejandro Zevallos , Pierina Danos-Diaz , Vanessa Perez-Silos , Mirna Rodriguez , Guangyao Gao , Wolf-Nicolas Fischer , Bernd Jandeleit , Ryan Wilcox
{"title":"Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas","authors":"Carlos Murga-Zamalloa ,&nbsp;Shaun Webb ,&nbsp;John Reneau ,&nbsp;Alejandro Zevallos ,&nbsp;Pierina Danos-Diaz ,&nbsp;Vanessa Perez-Silos ,&nbsp;Mirna Rodriguez ,&nbsp;Guangyao Gao ,&nbsp;Wolf-Nicolas Fischer ,&nbsp;Bernd Jandeleit ,&nbsp;Ryan Wilcox","doi":"10.1016/j.lrr.2023.100398","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100398","url":null,"abstract":"<div><p>T-cell lymphomas are aggressive neoplasms characterized by poor responses to current chemotherapeutic agents. Expression of the l-type amino acid transporter 1 (LAT 1, SLC7A5) allows for the expansion of healthy T-cell counterparts, and upregulation of LAT1 has been reported in precursor T-cell acute leukemia. Therefore, the expression of LAT1 was evaluated in a cohort of cutaneous and peripheral T-cell lymphomas. The findings demonstrated that LAT1 is upregulated in aggressive variants and absent in low-grade or indolent disease such as mycosis fungoides. In addition, upregulated LAT1 expression was seen in a large proportion of aggressive peripheral T-cell lymphomas, including peripheral T-cell lymphoma not otherwise specific (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). The anti-tumor effects of two novel non-cleavable and bifunctional compounds, QBS10072S and QBS10096S, that combine a potent cytotoxic chemotherapeutic domain (tertiary N-bis(2-chloroethyl)amine) with the structural features of a selective LAT1 substrate (aromatic β-amino acid) were tested in vitro and in vivo in T-cell lymphoma cell lines. The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100398"},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000389/pdfft?md5=c638ea237da29a9a7493e919985d5f1a&pid=1-s2.0-S2213048923000389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138738945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm. 将 Venetoclax 单药疗法作为水泡性浆细胞树突状细胞肿瘤的一线疗法。
Leukemia Research Reports Pub Date : 2023-07-03 eCollection Date: 2023-01-01 DOI: 10.1016/j.lrr.2023.100380
Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang
{"title":"Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm.","authors":"Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang","doi":"10.1016/j.lrr.2023.100380","DOIUrl":"10.1016/j.lrr.2023.100380","url":null,"abstract":"<p><p>Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted in rapid complete resolution of skin lesions, however, treatment interruption due to neutropenia led to brisk cancer recurrence. Fortunately, the patient responded to re-challenge and was able to undergo HCT. Venetoclax is active in the first-line treatment setting for BPDCN, however its effect on blood counts and durability of response should be further studied.</p>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"1 1","pages":"100380"},"PeriodicalIF":0.0,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54768411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm Venetoclax单药治疗作为母细胞浆细胞样树突状细胞肿瘤的一线治疗
Leukemia Research Reports Pub Date : 2023-07-03 DOI: 10.1016/j.lrr.2023.100380
Ankit Mitesh Shah , Denise Pereira , Julio Poveda , Trent Peng Wang
{"title":"Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm","authors":"Ankit Mitesh Shah ,&nbsp;Denise Pereira ,&nbsp;Julio Poveda ,&nbsp;Trent Peng Wang","doi":"10.1016/j.lrr.2023.100380","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100380","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"20 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49899181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum 细胞遗传学异常对症状性多发性骨髓瘤的影响关西骨髓瘤论坛对日本现实世界的分析
Leukemia Research Reports Pub Date : 2023-01-01 DOI: 10.1016/j.lrr.2023.100395
Aya Nakaya , Hirohiko Shibayama , Nobuhiko Uoshima , Ryosuke Yamamura , Satoshi Yoshioka , Kazunori Imada , Yuji Shimura , Masaaki Hotta , Toshimitsu Matsui , Satoru Kosugi , Hitoshi Hanamoto , Hitoji Uchiyama , Satoshi Yoshihara , Shin-ichi Fuchida , Yoshiyuki Onda , Yasuhiro Tanaka , Kensuke Ohta , Mitsuhiro Matsuda , Junya Kanda , Adachi Yoko , Masayuki Hino
{"title":"Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum","authors":"Aya Nakaya ,&nbsp;Hirohiko Shibayama ,&nbsp;Nobuhiko Uoshima ,&nbsp;Ryosuke Yamamura ,&nbsp;Satoshi Yoshioka ,&nbsp;Kazunori Imada ,&nbsp;Yuji Shimura ,&nbsp;Masaaki Hotta ,&nbsp;Toshimitsu Matsui ,&nbsp;Satoru Kosugi ,&nbsp;Hitoshi Hanamoto ,&nbsp;Hitoji Uchiyama ,&nbsp;Satoshi Yoshihara ,&nbsp;Shin-ichi Fuchida ,&nbsp;Yoshiyuki Onda ,&nbsp;Yasuhiro Tanaka ,&nbsp;Kensuke Ohta ,&nbsp;Mitsuhiro Matsuda ,&nbsp;Junya Kanda ,&nbsp;Adachi Yoko ,&nbsp;Masayuki Hino","doi":"10.1016/j.lrr.2023.100395","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100395","url":null,"abstract":"<div><p>To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnosis. In the high-risk group analysis, the median OS of patients without CAs (<em>n</em> = 338, 72 %) was 6.5 years, patients with del(17p) (<em>n</em> = 42, 9 %) was 4.4 years, patients with t(4;14) or t(14;16) (<em>n</em> = 72, 15 %) was 4.4 years, and patients with double-positive CAs(del(17p) and t(4;14) or t(14;16)) (<em>n</em> = 18, 4 %) was 2.1 years (<em>p</em> = 0.032). Patients with double-positive CAs had a significantly worse prognosis.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"20 ","pages":"Article 100395"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048923000353/pdfft?md5=da41e0ae4551170b1083dfbc3d685562&pid=1-s2.0-S2213048923000353-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138435663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信